methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(2-ethenylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate | 1120330-47-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(2-ethenylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
• CAS: 1120330-47-3
• 化学式: C₂₅H₃₀O₈
• 分子量: 458.508
• InChiKey: XNVZMIQGQHRIQL-OKIGDJELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(2-ethenylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 以88%的产率得到(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2-ethylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate
  参考文献：
  名称：

  Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues

  摘要：

  The neoclerodane diterpene salvinorin A, found in the leaves of Salvia divinorum, is a potent kappa-opioid receptor agonist, making it an attractive scaffold for development into a treatment for substance abuse. Although several successful semisynthetic studies have been performed to elucidate structure-activity relationships, the lack of analogues with substitutions to the furan ring of salvinorin A has prevented a thorough understanding of its role in binding to the kappa-opioid receptor. Herein we report the synthesis of several salvinorin A derivatives with modified furan rings. Evaluation of these compounds in a functional assay indicated that sterically less demanding substitutions are preferred, suggesting the furan ring is bound in a congested portion of the binding pocket. The most potent of the analogues successfully reduced drug-seeking behavior in an animal model of drug-relapse without producing the sedation observed with other kappa-opioid agonists.

  DOI：

  10.1021/jm501521d
• 作为产物：
  描述：

  丹酚 A 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 溴 、 caesium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(2-ethenylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
  参考文献：
  名称：

  Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues

  摘要：

  The neoclerodane diterpene salvinorin A, found in the leaves of Salvia divinorum, is a potent kappa-opioid receptor agonist, making it an attractive scaffold for development into a treatment for substance abuse. Although several successful semisynthetic studies have been performed to elucidate structure-activity relationships, the lack of analogues with substitutions to the furan ring of salvinorin A has prevented a thorough understanding of its role in binding to the kappa-opioid receptor. Herein we report the synthesis of several salvinorin A derivatives with modified furan rings. Evaluation of these compounds in a functional assay indicated that sterically less demanding substitutions are preferred, suggesting the furan ring is bound in a congested portion of the binding pocket. The most potent of the analogues successfully reduced drug-seeking behavior in an animal model of drug-relapse without producing the sedation observed with other kappa-opioid agonists.

  DOI：

  10.1021/jm501521d

文献信息

• Modification of the furan ring of salvinorin A: Identification of a selective partial agonist at the kappa opioid receptor
  作者：Cécile Béguin、Katharine K. Duncan、Thomas A. Munro、Douglas M. Ho、Wei Xu、Lee-Yuan Liu-Chen、William A. Carlezon、Bruce M. Cohen

  DOI：10.1016/j.bmc.2008.12.012

  日期：2009.2

  modified the furan ring of the highly potent and selective KOPR agonist salvinorin A. Introduction of small substituents at C-16 was well tolerated. 12-epi-Salvinorin A, synthesized in four steps from salvinorin A, was a selective partial agonist at the KOPR. No clear SAR patterns were observed for C-13 aryl ketones. Introducing a hydroxymethylene group between C-12 and the furan ring was tolerated. Small

  为了寻找选择性靶向κ阿片受体 (KOPR) 的新型药物，我们修改了高效选择性 KOPR 激动剂 SAlvinorin A 的呋喃环。在 C-16 处引入小取代基的耐受性良好。12- epi- SAlvinorin A，由 SAlvinorin A 分四步合成，是 KOPR 的选择性部分激动剂。没有观察到 C-13 芳基酮的清晰 SAR 模式。在 C-12 和呋喃环之间引入羟基亚甲基是可以容忍的。小的 C-13 酯和醚产生弱的 KOPR 激动剂，而所有 C-13 酰胺均无活性。最后，用恶二唑取代呋喃环消除了对 KOPR 的亲和力。没有一种化合物显示出任何 KOPR 拮抗作用或对 mu 或 delta 阿片受体的任何亲和力。
• [EN] SALVINORIN DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SALVINORINE ET LEURS UTILISATIONS
  申请人：MCLEAN HOSPITAL CORP

  公开号：WO2010075045A1

  公开（公告）日：2010-07-01

  The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.

  该发明涉及选择性作用于κ阿片受体的salvinorin组合物；利用选择性κ受体激动剂治疗躁狂症的方法；以及利用salvinorin组合物治疗情绪障碍，如抑郁障碍和躁狂障碍的方法。
• SALVINORIN DERIVATIVES AND USES THEREOF
  申请人：Beguin Cecile

  公开号：US20120010219A1

  公开（公告）日：2012-01-12

  The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.

  该发明涉及选择性作用于kappa阿片受体的沙尔维诺林组合物；利用选择性kappa受体激动剂治疗躁狂症的方法；以及利用沙尔维诺林组合物治疗情感障碍，如抑郁症和躁郁症的方法。
• COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA
  申请人：BLUMENTECH, S.L.

  公开号：US20210186927A1

  公开（公告）日：2021-06-24

  The state of general anesthesia (GA) is essential to many surgical and medical procedures. This state is characterized by loss of consciousness, deep analgesia and suppression of movements. GA is rarely achieved with a single drug, usually requiring the combination of various pharmacological agents. Each drug can interact with one or more molecular targets affecting neuronal excitability and synaptic transmission in multiple regions of the CNS. Agonists of the μ-opioid receptor are commonly used in GA to cause analgesia, but not to induce or maintain loss of consciousness or movement suppression. Additionally, agonists of the μ-opioid receptor can cause serious unwanted side effects, e.g. respiratory depression. The present invention provides alternative combination products based on K-opioid receptor agonists. These combination products unexpectedly induced loss of consciousness, and were able to achieve and maintain GA. Furthermore, the combination products suppressed pain perception without the need of a μ-opioid receptor agonist. The combination of Salvinorin A, a selective κ-opioid receptor agonist, with Diazepam or Medetomidine surprisingly led to rapid consciousness, deep analgesia and movement suppression. This combination was found to effectively induce and maintain a state of general anesthesia.
• US8492564B2
  申请人：——

  公开号：US8492564B2

  公开（公告）日：2013-07-23